DLX5通过对c-Myc表达的升级来促进细胞癌中的放射电阻
Danfei Hu1, Mingyao Li1, Xiaodong Chen2
1Department of Radiation Oncology, Ningbo Medical Center Lihuili Hospital, 315000,Ningbo, Zhejiang, China.
Frontiers in bioscience (Landmark edition)
|November 30, 2024
概括
远端无本体5 (DLX5) 驱动细胞癌 (RCC) 的生长和辐射抵抗,通过增加c-Myc. 在RCC细胞中抑制DLX5可对抗放射电阻和瘤生长,提供潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 放射治疗研究 放射治疗研究
背景情况:
- 细胞癌 (RCC) 是一种具有高转移潜力的侵袭性癌症.
- 放射治疗对于转移性RCC至关重要,但由于放射电阻,它面临着挑战.
- 在各种癌症中,Distal-less homeobox 5 (DLX5) 的致癌作用表明它参与了RCC的放射电阻.
研究的目的:
- 调查DLX5在细胞癌中放射电阻的发展中的作用.
- 探索DLX5影响RCC电阻的潜在机制.
- 评估DLX5作为一个潜在的治疗目标,以克服RCC中的放射电阻.
主要方法:
- 在RCC组织和细胞系中分析DLX5表达.
- 在RCC细胞 (786-O,Caki-1) 中使用si-DLX5.5使DLX5沉默.
- 用CCK-8,EDU,流细胞计,殖民地形成和免疫光测试来评估细胞增殖,亡,放射电阻和DNA损伤.
- 通过西部斑块,殖民地形成和CCK-8试验来探索机制.
- 在体内效应使用异种移植小鼠模型进行了研究.
主要成果:
- 在RCC组织和细胞系中DLX5表达显著升高.
- 在实验室中,DLX5敲击降低了RCC细胞增殖,诱导了亡,降低了放射电阻,并增强了DNA损伤.
- 机理学研究表明DLX5可调节c-Myc,促进放射电阻.
- 在体内,DLX5沉默抑制了瘤生长并减少了放射电阻.
结论:
- DLX5在促进细胞癌细胞生长和辐射抵抗方面发挥着至关重要的作用.
- DLX5对c-Myc的上调调节是RCC中驱动放射电阻的关键机制.
- 向DLX5为克服细胞癌治疗中的放射电阻提供了一个有希望的策略.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.6K
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
3.2K
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
